When we treated NSCLC cells expressing EGFR-mutant and containing the BIM deletion polymorphism with ABT-737 and erlotinib BIM containing a BH3 domain was restored, and eventually erlotinib resistance was overcome. Here, BCL2L11 is linked to non-small cell lung carcinoma.